FDA Grants Priority Review to Nirogacestat for Desmoid Tumors

Article

Findings from the phase 3 DeFi trial support the new drug application for nirogacestat as a treatment for adults with desmoid tumors.

The FDA has accepted and granted priority review to an investigational new drug application for nirogacestat as a treatment for adult patients with desmoid tumors, according to a press release from SpringWorks Therapeutics.1

"The acceptance of our [new drug application] for nirogacestat with priority review represents a significant milestone in our ambition to provide the first approved therapy for patients with desmoid tumors," according to the manufacturers of nirogacestat.

"The acceptance of our [new drug application] for nirogacestat with priority review represents a significant milestone in our ambition to provide the first approved therapy for patients with desmoid tumors," according to the manufacturers of nirogacestat.

The FDA has set a Prescription Drug User Fee Act date for August 27, 2023.

The investigational new drug application was supported by data from the phase 3 DeFi trial (NCT03785964), which read out at the 2022 European Society for Medical Oncology Congress (ESMO).

In the DeFi trial, the median progression-free survival (PFS) was not reached with nirogacestat compared with 15.1 months in the placebo arm; the former demonstrated a 71% reduction in the risk of disease progression (HR, 0.29; 95% CI, 0.15-0.55; P <.001).2 Additionally, nirogacestat yielded a PFS benefit across all prespecified subgroups based on factors such as gender, tumor location, prior treatment or surgery, and mutational status.

“The acceptance of our [new drug application] for nirogacestat with priority review represents a significant milestone in our ambition to provide the first approved therapy for patients with desmoid tumors,” Saqib Islam, chief executive officer at SpringWorks, said in the press release.

Investigators of the global, randomized, double-blind, placebo-controlled phase 3 DeFi trial compared the efficacy and safety of nirogacestat with placebo in adult patients with progressing desmoid tumors. A total of 142 patients were randomly assigned 1:1 to either receive 150 mg of nirogacestat (n =70) or placebo (n = 72) twice a day.

The primary end point of the trial was PFS as assessed by blinded independent central review. Secondary and exploratory end points included safety, objective response rate (ORR), duration of response, changes in tumor volume, and patient-reported outcomes.

Patients 18 years and older with histologically confirmed desmoid tumors that have progressed by at least 20% per RECIST v1.1 guidelines within 12 months of screening were eligible for enrollment. Additional inclusion criteria included having provided archival or new tumor tissue for reconfirmation of disease, an ECOG performance status of 2 or lower, and adequate organ and bone marrow function.

Confirmed ORR in the DeFi trial was 41% with nirogacestat vs 8% with placebo (P <.001), with complete response rates of 7% vs 0%. Additionally, nirogacestat produced statistically significant and clinically meaningful improvements in patient-reported outcomes including pain reduction (P <.001), other desmoid tumor-specific symptoms (P <.001), improved physical role functioning (P <.001), and overall health-related quality of life (P = .007).

Overall, 95% of treatment-emergent adverse effects (TEAEs) following nirogacestat therapy were grade 1 or 2. The most frequent TEAEs in the nirogacestat and placebo arms, respectively, included diarrhea (84% vs 35%), nausea (54% vs 39%), and fatigue (51% vs 36%). In each respective arm, dose reductions due to TEAEs occurred in 42% vs 0%, and treatment discontinuation due to TEAEs was necessary in 20% vs 1%, respectively.

Investigators observed ovarian dysfunction in 75% (n = 27/36) of patients of childbearing potential who received nirogacestat. Of these patients, 74% had their AEs resolve, including 64% who remained on nirogacestat treatment.

References

  1. SpringWorks Therapeutics announces FDA acceptance and priority review of new drug application for nirogacestat for the treatment of adults with desmoid tumors. News release. SpringWorks Therapeutics. February 27, 2023. Accessed February 27, 2023. bit.ly/3SxA1Qk
  2. SpringWorks Therapeutics announces data from phase 3 DeFi trial evaluating nirogacestat in adult patients with progressing desmoid tumors at the European Society for Medical Oncology (ESMO) Congress 2022. News release. September 10, 2022. Accessed February 27, 2023. bit.ly/3YWB2Ux
Recent Videos
According to John Henson, MD, “What we need are better treatments to control the [brain] tumor once it’s detected.”
First-degree relatives of patients who passed away from pancreatic cancer should be genetically tested to identify their risk for the disease.
Destigmatizing cancer care for incarcerated patients may help ensure that they feel supported both in their treatment and their humanity.
A lower percentage of patients who were released within 1 year of incarceration received guideline-concurrent care vs incarcerated patients.
A collaboration between the Connecticut Departments of Health and Corrections and the COPPER Center aimed to improve outcomes among incarcerated patients.
Computational models help researchers anticipate how ADCs may behave in later lines of development, while they are still in the early stages.
ADC payloads with high levels of potency can sometimes lead to higher levels of toxicity, which can eliminate the therapeutic window for patients with cancer.
According to Greg Thurber, PhD, target-mediated uptake is the biggest driver of efficacy for antibody-drug conjugates as a cancer treatment.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to expect at the 43rd Annual Chemotherapy Foundation Symposium, such as new chemotherapeutics and targeted therapies.
In neuroendocrine tumor management, patients with insulinoma may be at risk of severe hypoglycemia following receipt of GLP-1 receptor agonists.
Related Content
Rising cancer diagnoses in the US highlight urgent needs for improved oncology education, workforce distribution, and care infrastructure, especially in rural areas.

A Decline in the US Oncology Workforce: What Will the Next Decade Bring?

Julie M. Vose, MD, MBA
December 2nd 2025
Article

Rising cancer diagnoses in the US highlight urgent needs for improved oncology education, workforce distribution, and care infrastructure, especially in rural areas.

Decision-Making Capacity: The Ethical Core of Patient-Centered Oncology

Decision-Making Capacity: The Ethical Core of Patient-Centered Oncology

Daniel C. McFarland, DO;Louis P. Voigt, MD;Yesne Alici, MD
November 24th 2025
Podcast

Daniel C. McFarland, DO, is joined by Louis P. Voigt, MD, and Yesne Alici, MD, who focused on decision-making capacity and patient-centered care.

PAS-004 was deemed safe and tolerable when given in 37 mg capsules, so the trial will proceed to administer the agent in 45 mg capsules.

Cohort 7 of Novel MEK Inhibitor Trial Completed for MAPK Pathway-Driven Tumors

Tim Cortese
November 25th 2025
Article

PAS-004 was deemed safe and tolerable when given in 37 mg capsules, so the trial will proceed to administer the agent in 45 mg capsules.

Experts discussed supportive care and why it should be integrated into standard oncology care.

How Supportive Care Methods Can Improve Oncology Outcomes

Declan Walsh, MD;Denise B. Reynolds, RD;Adam Friedman, MD, FAAD;Daniel C. McFarland, DO;Michelle Fingeret, PhD;Christian J. Nelson, PhD;William S. Breitbart, MD
November 10th 2025
Podcast

Experts discussed supportive care and why it should be integrated into standard oncology care.

Novel Agent Yields Promising Results in MAPK-Associated Solid Tumors

Novel Agent Yields Promising Results in MAPK-Associated Solid Tumors

Ariana Pelosci
November 21st 2025
Article

Partial responses and stable disease were observed with PAS-004 in patients with advanced solid tumors harboring RAS, NF1, or RAF mutations.

Results from the C-POST trial showed that cemiplimab improved DFS vs placebo in patients with CSCC at high risk of recurrence following surgery and radiation.

EC Approves Adjuvant Cemiplimab in CSCC at High Risk of Recurrence

Tim Cortese
November 20th 2025
Article

Results from the C-POST trial showed that cemiplimab improved DFS vs placebo in patients with CSCC at high risk of recurrence following surgery and radiation.